Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

Galapagos and CHDI enter new collaboration agreements
November 2008
SHARING OPTIONS:

MECHELEN, BelgiumóGalapagos NV and Los Angeles-based CHDI Foundation Inc., a non-profit organization pursuing treatments for Huntington's disease (HD), announced in late October a new collaboration focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD. Total value of the contracts for Galapagos is $1 million over 1.5 years. Galapagos' service division, BioFocus DPI, will develop a high-throughput screening assay in mouse neurons that will enable the identification of compounds that prevent neuronal dysfunction associated with HD. BioFocus DPI will also make use of its expertise in profiling and assay development to evaluate known compounds inhibiting certain enzymes playing key roles in HD. DDN

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.